Combined Exendin-4 and Rituximab Treatment Improves β-Cell Function and Delays Disease Progression in NOD Mice
TL;DR
The combined treatment of rituximab and exendin-4 improved insulin-related responses, helped maintain more stable blood glucose levels, improved glucose tolerance, and delayed the development of high blood sugar.
Abstract
Simple Summary Type 1 diabetes develops when the immune system damages the insulin-producing cells of the pancreas, leading to a progressive loss of insulin production and poor blood sugar control. In this study, we investigated whether combining rituximab, an antibody-based treatment previously investigated in type 1 diabetes, with exendin-4, a drug that supports insulin-producing cell function, could provide greater benefits than either treatment alone. Experiments were performed using isolated pancreatic islets and a mouse model of type 1 diabetes. The combined treatment improved insulin-related responses, helped maintain more stable blood glucose levels, improved glucose tolerance, and delayed the development of high blood sugar. It was also associated with better preservation of pancreatic islet structure, reduced inflammatory damage, and fewer signs related to cell death. These findings support further investigation of combined rituximab and exendin-4 treatment as a potential strategy for preserving islet function and delaying disease progression in early-stage type 1 diabetes.